These products are estimated to have a generic market size of ZAR 165 million in the local market, the company said in a filing to the Bombay Stock Exchange.
Aurobindo now has a total of 31 marketing authorisations approved by the MCC, the company added.
Out of the nine products -- Zinoxime and Yomax -- are anti-infective while Auro-Lisinopril Co, Auro-Amlodipine and Lisinozide are cardio-vascular system drug.
The other products that received the approval include -- Auro-Finasteride, Zolid, Lazivir and Profina.
Shares of the company were trading at Rs 330, down 2.21 per cent on the BSE in afternoon trade.
